The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Regulation of pulmonary fibrosis by chemokine receptor CXCR3
Open accessAbstract
CXC chemokine receptor 3 (CXCR3) is the receptor for the IFN-γ-inducible C-X-C chemokines MIG/CXCL9, IP-10/ CXCL10, and I-TAC/CXCL11.CXCR3 is expressed on activated immune cells and proliferating endothelial cells.The role of CXCR3 in fibroproliferation has not been investigated.We examined the role of CXCR3 in pulmonary injury and repair in vivo.CXCR3-deficient mice demonstrated increased mortality with progressive interstitial fibrosis relative to WT mice.Increased fibrosis occurred without increased inflammatory cell recruitment.CXCR3 deficiency resulted in both a reduced early burst of IFN-γ production and decreased expression of CXCL10 after lung injury.We identified a relative deficiency in lung NK cells in the unchallenged CXCR3-deficient lung and demonstrated production of IFN-γ by WT lung NK cells in vivo following lung injury.The fibrotic phenotype in the CXCR3-deficient mice was significantly reversed following administration of exogenous IFN-γ or restoration of endogenous IFN-γ production by adoptive transfer of WT lymph node and spleen cells.Finally, pretreatment of WT mice with IFN-γ-neutralizing Ab's enhanced fibrosis following lung injury.These data demonstrate a nonredundant role for CXCR3 in limiting tissue fibroproliferation and suggest that this effect may be mediated, in part, by the innate production of IFN-γ following lung injury.Nonstandard abbreviations used: bronchoalveolar lavage (BAL); CXC chemokine receptor 3 (CXCR3); idiopathic interstitial pneumonia (IIP); idiopathic pulmonary fibrosis (IPF).Conflict of interest: P. Noble is a paid consultant for Intermune Pharmaceuticals, who is developing IFN-�1b for therapeutic use in patients with pulmonary fibrosis.R. Homer has received honoraria from Intermune Pharmaceuticals for lecturing at CME-sponsored programs on the pathology of idiopathic pulmonary fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Qin, S., Rottman, J. B., Myers, P., Kassam, N., Weinblatt, M., Loetscher, M., Koch, A. E., Moser, B., & Mackay, C. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1422 · Cited by 1,359
Lee, C. G., Homer, R. J., Zhu, Z., Lanone, S., Wang, X., Koteliansky, V., Shipley, J. M., Gotwals, P., Noble, P., Chen, Q., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.809 · Cited by 940
Self-citationCole, K. E., Strick, C. A., Paradis, T. J., Ogborne, K. T., Loetscher, M., Gladue, R. P., Lin, W., Boyd, J. G., Moser, B., Wood, D. E., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2009 · Cited by 870
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030511 · Cited by 652
Self-citationZiesche, R., Hofbauer, E., Wittmann, K., Petkov, V., & Block, L.-H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411703 · Cited by 586
IL-12 attenuates bleomycin-induced pulmonary fibrosis
Keane, M. P., Belperio, J. A., Burdick, M. D., & Strieter, R. M. (2001) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2001.281.1.l92 · Cited by 146
Cited by
The trafficking of natural killer cells
Grégoire, C., Chasson, L., Luci, C., Tomasello, E., Geissmann, F., Vivier, E., & Walzer, T. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00563.x · Cited by 569
Matrix Metalloproteinases as Therapeutic Targets for Idiopathic Pulmonary Fibrosis
Craig, V. J., Zhang, L., Hagood, J. S., & Owen, C. A. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0020tr · Cited by 507
A Vicious Circle of Alveolar Macrophages and Fibroblasts Perpetuates Pulmonary Fibrosis via CCL18
Prasse, A., Pechkovsky, D. V., Toews, G. B., Jungraithmayr, W., Kollert, F., Goldmann, T., Vollmer, E., Müller-Quernheim, J., & Zissel, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200509-1518oc · Cited by 497
Organ-specific features of natural killer cells
Shi, F.-D., Ljunggren, H.-G., La Cava, A., & Van Kaer, L. (2011) · Nature Reviews Immunology · doi:10.1038/nri3065 · Cited by 414
Liang, J., Zhang, Y., Xie, T., Liu, N., Chen, H., Geng, Y., Kurkciyan, A., Mena, J. M., Stripp, B. R., Jiang, D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4192 · Cited by 287
Self-citation
Metadata
- Authors
- Jiang, D., Liang, J., Hodge, J., Lu, B., Zhu, Z., Yu, S., Fan, J., Gao, Y., Yin, Z., Homer, R., Gerard, C., & Noble, P. W.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-07-15
- Volume
- 114
- Issue
- 2
- Pages
- 291-299
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2120446140
- Cited by
- 303
- References
- 7
- FWCI
- 15.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regulation of pulmonary fibrosis by chemokine receptor CXCR3. https://app.cochat.ai/papers/10.1172/jci16861
- The paper
- Jiang, D., Liang, J., Hodge, J., Lu, B., Zhu, Z., Yu, S., Fan, J., Gao, Y., Yin, Z., Homer, R., Gerard, C., & Noble, P. W. (2004). Regulation of pulmonary fibrosis by chemokine receptor CXCR3. Journal of Clinical Investigation. https://doi.org/10.1172/jci16861
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
